A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Fox, Christopher B ^a   Sivananthan, Sandra J ^a   Duthie, Malcolm S ^a   Vergara, Julie ^a   Guderian, Jeffrey A ^a   Moon, Elliot ^b   Coblentz, David ^b   Reed, Steven G ^a   Carter, Darrick ^a,c  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b DF/Net Research   (United States)

^c PAI Life Sciences   (United States)

Author keywords

Adjuvant; Liposome; Manufacturability; Synergy; TLR4; TLR7

Indexed keywords

ANTIGENS; IMMUNE SYSTEM; LIPID BILAYERS; LIPOSOMES; MAMMALS;

ADJUVANT; MANUFACTURABILITY; SYNERGY; TLR4; TLR7;

LIGANDS;

GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; NANOCARRIER; NANOLIPOSOME; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; FILTRATION; HUMAN; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LIPID BILAYER; LIPOSOMAL DELIVERY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; DRUG SYNERGISM; FEMALE; HUMANS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED C57BL; TH1 CELLS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7;

EID: 84899928563     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-12-17     Document Type: Article

References (45)

1. Carter D, Reed SG. Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS 2010, 5:409-413. 410.1097/COH.1090b1013e32833d32832cdb.
2. Ansong D, Asante KP, Vekemans J, Owusu SK, Owusu R, Brobby NAW, Dosoo D, Osei-Akoto A, Osei-Kwakye K, Asafo-Adjei E, Boahen KO, Sylverken J, Adjei G, Sambian D, Apanga S, Kayan K, Janssens MH, Lievens MJJ, Olivier AC, Jongert E, Dubois P, Savarese BM, Cohen J, Antwi S, Greenwood BM, Evans JA, Agbenyega T, Moris PJ, Owusu-Agyei S. T cell responses to the RTS,S/AS01E and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One 2011, 6:e18891.
3. Harper DM, Vierthaler SL. Next generation cancer protection: the bivalent HPV vaccine for females. ISRN Obstet Gynecol 2011, 2011:457204.
4. Ray A, Cot M, Puzo G, Gilleron M, Nigou J. Bacterial cell wall macroamphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie 2013, 95:33-42.
5. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006, 22:561-569.
6. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
7. Song DH, Lee JO. Sensing of microbial molecular patterns by Toll-like receptors. Immunol Rev 2012, 250:216-229.
8. Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 2009, 27:3045-3052.
9. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
10. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
11. Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006, 18:1115-1126.
12. Malhotra D, Relhan V, Reddy BS, Bamezai R. TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum Genet 2005, 116:413-415.
13. Kawai T, Akira S. TLR signaling. Semin Immunol 2007, 19:24-32.
14. Miggin SM, O'Neill LA. New insights into the regulation of TLR signaling. J Leukoc Biol 2006, 80:220-226.
15. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, O'Donnell J, Pattabhi S, Guderian JA, Mohamath R, Duthie MS, Reed SG. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 2010, 185:1701-1710.
16. Brosbol-Ravnborg A, Bundgaard B, Hollsberg P. Synergy between vitamin D3 and Toll-like receptor agonists regulates human dendritic cell response during maturation. Clin Dev Immunol 2013, 2013:807971.
17. Pone EJ, Zhang J, Mai T, White CA, Li G, Sakakura JK, Patel PJ, Al-Qahtani A, Zan H, Xu Z, Casali P. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway. Nat Commun 2012, 3:767.
18. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
19. Zhang WW, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 2008, 76:3777-3783.
20. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garcon N. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
21. El-On J, Bazarsky E, Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod. Exp Parasitol 2007, 116:156-162.
22. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
23. Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR, Reed SG, Chitnis CE, Carter D. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 2011, 3:93ra69.
24. Ali OA, Verbeke C, Johnson C, Sands W, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ. Identification of immune factors regulating anti-tumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res 2014, 74:1670-1681.
25. Shima F, Uto T, Akagi T, Akashi M. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(gamma-glutamic acid)-based nanoparticles as vaccine adjuvants. Bioconjug Chem 2013, 24:926-933.
26. Yang M, Flavin K, Kopf I, Radics G, Hearnden CH, McManus GJ, Moran B, Villalta-Cerdas A, Echegoyen LA, Giordani S, Lavelle EC. Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation. Small 2013, 9:4194-4206.
27. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008, 4:e1000138.
28. Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010, 116:564-574.
29. Invivogen Imiquimod - R837 technical data sheet. 2013, Invivogen.
30. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
31. Chollet JL, Jozwiakowski MJ, Phares KR, Reiter MJ, Roddy PJ, Schultz HJ, Ta QV, Tomai MA. Development of a topically active imiquimod formulation. Pharm Dev Technol 1999, 4:35-43.
32. Hayashi T, Crain B, Corr M, Chan M, Cottam HB, Maj R, Barberis A, Leoni L, Carson DA. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol 2010, 17:483-490.
33. Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, Vergunst H, de Reijke TM, Witjes JA. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol 2013, 189:2077-2082.
34. Arentsen HC, de Kaa CA H-V, Jansen CF, Maj R, Leoni LM, Oosterwijk E, Witjes JA. Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int 2011, 108:1210-1214.
35. Food and Drug Administration Inactive ingredient search for approved drug products U.S. Food and Drug Administration, Food and Drug Administration.
36. Alkan SS. Skills, knowledge, and translational technologies leading to novel vaccines. Development of novel vaccines: skills, knowledge and translational technologies 2006, 1-2. New York: Springer, Von Gabain A, Klade C.
37. Fransson J, Espander-Jansson A. Local tolerance of subcutaneous injections. J Pharm Pharmacol 1996, 48:1012-1015.
38. Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 2013, 172:190-200.
39. Barenholz Y. Doxil® - The first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
40. Fenske DB, Maurer N, Cullis PR. Encapsulation of weakly-basic drugs, antisense oligonucleotides, and plasmid DNA within large unilamellar vesicles for drug delivery applications. Liposomes: a practical approach 2003, New York: Oxford University Press, Torchilin VP, Weissig V, 2.
41. Xu X, Khan MA, Burgess DJ. Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm 2012, 423:410-418.
42. Edholm O, Nagle JF. Areas of molecules in membranes consisting of mixtures. Biophys J 2005, 89:1827-1832.
43. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Coll Surf B: Biointerfaces 2010, 75:123-132.
44. Fox CB. Characterization of TLR4 agonist effects on Alhydrogel sedimentation: a novel application of laser scattering optical profiling. J Pharm Sci 2012, 101:4357-4364.
45. Misquith A, Fung HWM, Dowling QM, Guderian JA, Vedvick TS, Fox CB. In vitro evaluation of TLR4 agonist activity: formulation effects. Colloids Surf B: Biointerfaces 2014, 113:312-319.